ACTION3 Statistical Review Complete
Filed with ASX · · 4 pages · English
Earlier from Dimerix
- Dimerix to Conduct Review of ACTION3 Statistical Assumptions
- Dimerix Phase 3 Trial Last Patient Receives First Dose
- Appendix 4D and Half Year Financial Report
- Quarterly Appendix 4C and Activities Report
- BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
Later from Dimerix
- Blinded assessment of ACTION3 statistical assumptions complete
- Dimerix Quarterly Activities Report and Appendix 4C
- Dimerix Licenses DMX200 to Everest for China and Asia Region
- Dimerix exclusively licenses DMX-200 in Greater China, South Korea and Southeast Asia to Everest Medicines
- DMX-200 Available To Patients Via Post-Trial Access Pathways
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix